Beneficial cardiovascular pleiotropic effects of statins

被引:739
作者
Davignon, J [1 ]
机构
[1] Clin Res Inst Montreal, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada
关键词
endothelial dysfunction; inflammation; oxidation; pleiotropic effects; statins;
D O I
10.1161/01.CIR.0000131517.20177.5a
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pleiotropic effects of a drug are actions other than those for which the agent was specifically developed. These effects may be related or unrelated to the primary mechanism of action of the drug, and they are usually unanticipated. Pleiotropic effects may be undesirable (such as side effects or toxicity), neutral, or, as is especially the case with HMG-CoA reductase inhibitors (statins), beneficial. Pleiotropic effects of statins include improvement of endothelial dysfunction, increased nitric oxide bioavailability, antioxidant properties, inhibition of inflammatory responses, and stabilization of atherosclerotic plaques. These and several other emergent properties could act in concert with the potent low-density lipoprotein cholesterol -lowering effects of statins to exert early as well as lasting cardiovascular protective effects. Understanding the pleiotropic effects of statins is important to optimize their use in treatment and prevention of cardiovascular disease.
引用
收藏
页码:39 / 43
页数:5
相关论文
共 58 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[3]   Prevention of primary islet isograft nonfunction in mice with pravastatin [J].
Arita, S ;
Une, S ;
Ohtsuka, S ;
Atiya, A ;
Kasraie, A ;
Shevlin, L ;
Mullen, Y .
TRANSPLANTATION, 1998, 65 (11) :1429-1433
[4]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[5]   Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy [J].
Aviram, M ;
Hussein, O ;
Rosenblat, M ;
Schlezinger, S ;
Hayek, T ;
Keidar, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (01) :39-45
[6]   HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages [J].
Bellosta, S ;
Via, D ;
Canavesi, M ;
Pfister, P ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (11) :1671-1678
[7]   Novel clinical markers of vascular wall inflammation [J].
Blake, GJ ;
Ridker, PM .
CIRCULATION RESEARCH, 2001, 89 (09) :763-771
[8]   Statins and progressive renal disease [J].
Buemi, M ;
Senatore, M ;
Corica, F ;
Aloisi, C ;
Romeo, A ;
Cavallaro, E ;
Floccari, F ;
Tramontana, D ;
Frisina, N .
MEDICINAL RESEARCH REVIEWS, 2002, 22 (01) :76-83
[9]  
Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5
[10]   Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization [J].
Crisby, M ;
Nordin-Fredriksson, G ;
Shah, PK ;
Yano, J ;
Zhu, J ;
Nilsson, J .
CIRCULATION, 2001, 103 (07) :926-933